Click here to start your patients
on the path to just 2 DOSES A YEAR
- For US Healthcare Professionals Only
*Patients were required to have at least one schizophrenia-related index hospitalization during the study period defined using ICD-9 code 295.xx and ICD-10 codes F20.xx, F21.xx, or F25.xx. Coding selection included populations outside of the 2 approved indications of INVEGA SUSTENNA®. About 40% of the population had schizoaffective disorder, 33% had schizophrenia, and 3% had other diagnoses.
The Premier Perspective Comparative Hospital database, which encompasses inpatient services from over 700 hospitals in the US, was used to retrospectively compare rehospitalizations of adults with schizophrenia treated with paliperidone palmitate (n=8 578) or oral atypical antipsychotics (n=305 252) from January 2009 to December 2016.
Odds ratios were presented as a measure of effect, along with 95% confidence intervals and P values. A multivariate generalized estimating equation model, adjusted for a variety of demographic and clinical factors, was used to estimate the odds of rehospitalization for patients on paliperidone palmitate and oral atypical antipsychotics.
Results of retrospective studies can be affected by coding-entry errors, missing data, and residual confounding. The DSM-V criteria used in the clinical setting to diagnose patients with schizophrenia and schizoaffective disorders are not identical to the ICD-9 and ICD-10 codes used in this study to identify patients with schizophrenia and schizoaffective disorders. Since the date of the first schizophrenia diagnoses was not available, age was used as a surrogate for time from diagnosis. Patients could only be traced for hospitalizations occurring at the same facility, which could lead to underestimation of rehospitalization rates.
"An LAI formulation of an antipsychotic may also be considered when patients are transitioning between settings (e.g., at inpatient discharge, on release from a correctional facility), when future adherence is uncertain and the risk of reduced adherence may be increased."
Excerpt From the American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia3
†All-cause 30-day readmissions were seen in 19.3% of patients 18-44 years old and 19.7% of patients 45-64 years old.